Editas Medicine Quarterly Cash Flow Statement
NASDAQ: EDITHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Editas Medicine free cash flow
In the quarter ended Sep 30, 2026, Editas Medicine generated -$21.2 million of operating cash flow and spent $0 on capital expenditures. That left free cash flow of -$21.2 million, a free-cash-flow margin of -204.4% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Editas Medicine cash flow statement (quarterly)
| Quarter (USD) | Q3 20262026-09-30 | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -23.39M | -18.23M | -24.98M | -5.62M | -25.12M | -53.23M | -76.09M | -45.40M | -62.14M | -67.61M | -61.95M | -18.87M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 385.00K | 416.00K | 483.00K | 805.00K | 721.00K | 1.83M | 1.92M | 1.38M | 1.60M | 1.42M | 1.41M | 1.47M |
| Stock-Based Compensation | 2.57M | 2.19M | 2.10M | 2.13M | 2.23M | 2.66M | 2.98M | 4.02M | 4.80M | 5.01M | 7.58M | 5.34M |
| Change in Working Capital | -1.58M | -14.29M | 3.20M | -31.32M | -11.05M | -730.00K | 13.27M | -11.67M | 951.00K | 5.72M | 8.55M | -7.24M |
| Operating Cash Flow | -21.19M | -29.57M | -23.06M | -36.39M | -30.84M | -50.21M | -47.80M | -50.76M | -52.59M | -57.06M | -49.87M | -22.24M |
| Capital Expenditures | 0 | -106.00K | -92.00K | -60.00K | -433.00K | 0 | -114.00K | -540.00K | -2.92M | -3.49M | -1.87M | -1.31M |
| Investing Cash Flow | -66.99M | -29.80M | 64.00K | 58.00K | 39.57M | 42.65M | 56.39M | 30.96M | 83.98M | 51.95M | -4.75M | 62.84M |
| Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | -2.87M | 0 | 0 | 0 | 0 | — |
| Financing Cash Flow | -468.00K | 117.53M | 0 | 17.33M | 17.17M | 7.41M | -1.44M | 55.51M | 0 | 322.00K | 192.00K | 514.00K |
| Net Change in Cash | -88.65M | 58.17M | -23.00M | -19.00M | 25.90M | -150.00K | 7.15M | 35.71M | 31.39M | -4.79M | -54.42M | 41.11M |
| Free Cash Flow | -21.19M | -29.67M | -23.15M | -36.45M | -31.28M | -50.21M | -47.91M | -51.30M | -55.51M | -60.56M | -51.74M | -23.55M |
This table shows 12 quarterly periods of Editas Medicine's cash flow statement, from Q3 2026 back to Q4 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow EDIT's reporting calendar. What is a cash flow statement?